{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:17:23Z","timestamp":1792786643020,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["xzy012022112"],"award-info":[{"award-number":["xzy012022112"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shaanxi provincial Key R&D Program General Project","award":["2023-YBSF-196"],"award-info":[{"award-number":["2023-YBSF-196"]}]},{"DOI":"10.13039\/100031935","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["XJTU1AF-CRF-2020-013"],"award-info":[{"award-number":["XJTU1AF-CRF-2020-013"]}],"id":[{"id":"10.13039\/100031935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017592","name":"Key Science and Technology Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2020JQ-497"],"award-info":[{"award-number":["2020JQ-497"]}],"id":[{"id":"10.13039\/501100017592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903320"],"award-info":[{"award-number":["81903320"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Project of Xi'an Jiaotong University","id":[{"id":"https:\/\/ror.org\/017zhmm22","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Science and Technology Planning Project of Shaanxi Province"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jconrel.2025.113961","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:50:50Z","timestamp":1749898250000},"page":"113961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy"],"prefix":"10.1016","volume":"384","author":[{"given":"Xue","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiejun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linpei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangchuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7378","key":"10.1016\/j.jconrel.2025.113961_bb0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113961_bb0010","series-title":"T cell Costimulatory Receptor CD28 is a Primary Target for PD-1-mediated Inhibition","first-page":"1428","volume":"355(6332)","author":"Hui","year":"2017"},{"key":"10.1016\/j.jconrel.2025.113961_bb0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"issue":"7637","key":"10.1016\/j.jconrel.2025.113961_bb0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113961_bb0025","series-title":"The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy","first-page":"133","volume":"19(3)","author":"Havel","year":"2019"},{"issue":"25","key":"10.1016\/j.jconrel.2025.113961_bb0030","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6230","key":"10.1016\/j.jconrel.2025.113961_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113961_bb0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.113961_bb0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"Page","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2025.113961_bb0050","series-title":"Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave","volume":"9(11)","author":"Yu","year":"2021"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113961_bb0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"issue":"7718","key":"10.1016\/j.jconrel.2025.113961_bb0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113961_bb0065","series-title":"Immune Evasion Mediated by PD-L1 on Glioblastoma-derived Extracellular Vesicles","volume":"4(3)","author":"Ricklefs","year":"2018"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113961_bb0070","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113961_bb0075","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","article-title":"Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming","volume":"33","author":"Morrissey","year":"2021","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113961_bb0080","first-page":"787","article-title":"Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic","volume":"144","author":"Xie","year":"2022","journal-title":"Immunotherapy"},{"issue":"22","key":"10.1016\/j.jconrel.2025.113961_bb0085","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","article-title":"Posttranslational modifications of PD-L1 and their applications in cancer therapy","volume":"78","author":"Hsu","year":"2018","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113961_bb0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2025.113961_bb0095","series-title":"Promoting Anti-tumor Immunity by Targeting TMUB1 to Modulate PD-L1 Polyubiquitination and Glycosylation","first-page":"6951","volume":"13(1)","author":"Shi","year":"2022"},{"issue":"7686","key":"10.1016\/j.jconrel.2025.113961_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"7670","key":"10.1016\/j.jconrel.2025.113961_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113961_bb0110","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.113961_bb0115","series-title":"Glycosylation and Stabilization of Programmed Death Ligand-1 Suppresses T-cell Activity","first-page":"12632","volume":"7","author":"Li","year":"2016"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113961_bb0120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.jconrel.2025.113961_bb0125","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113961_bb0130","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","article-title":"MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1","volume":"156","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113961_bb0135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113961_bb0140","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113961_bb0145","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion","volume":"9","author":"Hsu","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113961_bb0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","article-title":"Palmitoylation stabilizes PD-L1 to promote breast tumor growth","volume":"29","author":"Yang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2025.113961_bb0155","series-title":"Inhibiting PD-L1 Palmitoylation Enhances T-cell Immune Responses Against Tumours","first-page":"306","volume":"3(4)","author":"Yao","year":"2019"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113961_bb0160","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0958-1669(97)80126-7","article-title":"Post-translational modification of proteins and the discovery of new medicine","volume":"8","author":"Parekh","year":"1997","journal-title":"Curr. Opin. Biotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113961_bb0165","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2025.113961_bb0170","series-title":"Immunostimulation With Chemotherapy in the Era of Immune Checkpoint Inhibitors","first-page":"725","volume":"17(12)","author":"Galluzzi","year":"2020"},{"key":"10.1016\/j.jconrel.2025.113961_bb0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","article-title":"Combining chemotherapy with PD-1 blockade in NSCLC","volume":"186","author":"Mathew","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.113961_bb0180","series-title":"Nanoparticle-mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy","first-page":"670","volume":"58(3)","author":"Duan","year":"2019"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113961_bb0185","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.jconrel.2025.113961_bb0190","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.jconrel.2025.113961_bb0195","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113961_bb0200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles","volume":"30","author":"Colombo","year":"2014","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2025.113961_bb0205","series-title":"Overcoming Primary and Acquired Resistance to anti-PD-L1 Therapy by Induction and Activation of Tumor-residing cDC1s","first-page":"5415","volume":"11(1)","author":"Oba","year":"2020"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113961_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002852","article-title":"STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation","volume":"9","author":"Nakamura","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.113961_bb0215","first-page":"10","article-title":"Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113961_bb0220","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc1391","article-title":"Hyaluronan: from extracellular glue to pericellular cue","volume":"4","author":"Toole","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113961_bb0225","first-page":"2592","article-title":"Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells","volume":"61","author":"Eliaz","year":"2001","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113961_bb0230","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","article-title":"The mechanisms of nanoparticle delivery to solid tumours","volume":"2","author":"Nguyen","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113961_bb0235","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1038\/s41467-023-40270-5","article-title":"Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113961_bb0240","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/nmat4718","article-title":"Mechanism of hard-nanomaterial clearance by the liver","volume":"15","author":"Tsoi","year":"2016","journal-title":"Nat. Mater."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113961_bb0245","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113961_bb0250","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29360","article-title":"Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113961_bb0255","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"issue":"6478","key":"10.1016\/j.jconrel.2025.113961_bb0260","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113961_bb0265","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/0008-5472.CAN-10-4455","article-title":"Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis","volume":"71","author":"Hood","year":"2011","journal-title":"Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:55:58Z","timestamp":1779512158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925005814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":53,"alternative-id":["S0168365925005814"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113961","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113961"}}